Your search history is turned on.
Date: April 25, 2024 Jurisdictions: Alberta, British Columbia, Ontario
VIA ELECTRONIC TRANSMISSION TO ALL APPLICABLE EXCHANGES AND COMMISSIONS: RE: NEXGENRX INC 1 Proxy with Request for Financial Statements - Registered Securityholders 2 Voting Instruction Form with Request for Financial Statements - NOBOs 3 Notice of Meeting 4 Information Circular 5 Proxy Return Envelope Yours truly, TSX Trust Company April 25, ...
Date: April 24, 2024 Jurisdictions: Alberta, British Columbia, Ontario
NEXGENRX INC (the "Corporation") Annual and Special Meeting May 16, 2024 at 11:00 AM (Canada/Eastern Standard) 191 The West Mall, Suite 905, Toronto, Ontario M9C 5L5 (the "Meeting") Proxy Voting Guidelines and Conditions THIS PROXY IS SOLICITED BY OR ON BEHALF OF THE MANAGEMENT OF THE CORPORATION. THIS PROXY SHOULD BE READ IN CONJUNCTION WITH THE MEETING MATERIAL...
NEXGENRX - Information Circular (2024 Annual and Special Meeting) - DRAFT (00733405-3).DOCX Information Circular Annual and Special Meeting May 16, 2024 Note re Meeting Attendance: The Meeting will held at the offices of NexgenRx inc., where space is limited. The meeting will also be audio-cast live at 11:0...
NEXGENRX - Notice of Annual and Special Meeting 2024 (PB0001).DOCX NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 16, 2024 NOTICE IS HEREBY GIVEN that the Annual and Special Meeting (the "Meeting") of the shareholders (the "Shareholders") of NexgenRx Inc. (the "Corporation") will be held at the offices of the Cor...
Date: April 5, 2024 Jurisdictions: Alberta, British Columbia, Ontario
NEXGENRX - Press Release (2023 Annual Results) (00733709).DOCX Toronto, Ontario, Canada April 5, 2024 TSX-V Symbol: NXG NEWS RELEASE NEXGENRX ANNOUNCES 2023 YEAR END RESULTS WITH SOLID REVENUE GROWTH, CONTINUING POSITIVE EBITDA For Immediate Release April 5, 2024: TORONTO, ONTARIO NEXGENRX INC. ("Ne...
Date: April 5, 2024 Jurisdictions: Alberta, Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, "EHLER", "kelly", an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasona...
Create participation fee form Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATI...
NEXGENRX - Annual CFO Certification re Dec 31-23 - conformed signature (00733580).DOCX FORM 52-109FV1 CERTIFICATION OF ANNUAL FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Kelly Ehler, Chief Financial Officer of NexgenRx Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including f...
NEXGENRX - Annual CEO Certification re Dec 31-23 conformed signature (00733581).DOCX FORM 52-109FV1 CERTIFICATION OF ANNUAL FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Ronald C. Loucks, President and Chief Executive Officer of NexgenRx Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&...
Microsoft Word - NexgenRx Inc.- Q4 2023 v4 December 31, 2023 Managements Discussion and Analysis NexgenRx Inc. For the year ended December 31, 2023 2 Table of Contents Presidents Message ........................................................................................................